Belong.Life rolls out online community for patients with chronic myeloid leukemia
Patients can use the service to access support groups, navigation tools  and a clinical trial-matching program. (Source: mobihealthnews)
Source: mobihealthnews - January 13, 2022 Category: Information Technology Source Type: news
How Long Can You Live With Chronic Myeloid Leukemia?
Title: How Long Can You Live With Chronic Myeloid Leukemia?Category: Diseases and ConditionsCreated: 1/7/2022 12:00:00 AMLast Editorial Review: 1/7/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - January 7, 2022 Category: Cancer & Oncology Source Type: news
Ibrutinib, (brand name Imbruvica), Can Keep Leukemia in Remission for Years in Younger Patients
TUESDAY, Dec. 14, 2021 -- For certain leukemia patients, some welcome findings: New research confirms long remissions after treatment with the drug ibrutinib and chemotherapy.
The study involved 85 patients with chronic lymphocytic leukemia (CLL).... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 14, 2021 Category: General Medicine Source Type: news
New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrated Deeper and Sustained Undetectable Minimal Residual Disease Outcomes in First-Line Chronic Lymphocytic Leukemia
ATLANTA, Ga., December 11, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from two studies evaluating the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) as a potential fixed-duration treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These data were both featured today during the American Society of Hematology (ASH) 2021 Annual Meeting. New secondary endpoint data from the Phase 3 GLOW study (NCT03462719) showed that fixed-duration treatment with I+V resulted in undetectable min...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Seeks Approval of IMBRUVICA ®(ibrutinib) in a Fixed-Duration Regimen for Patients with Untreated Chronic Lymphocytic Leukaemia (CLL)
BEERSE, BELGIUM, 30 November 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval of a new treatment option for IMBRUVICA® (ibrutinib) as a fixed-duration combination with venetoclax (I+V) for adult patients with previously untreated chronic lymphocytic leukaemia (CLL)."Ibrutinib was the first approved Bruton’s tyrosine kinase inhibitor and over the past seven years has become a key treatment for CLL and some other B-cell malignancies, treating more than 250,000 patients globally,â€...
Source: Johnson and Johnson - November 30, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Retrospective study finds that cancer drug also lowers blood glucose
ROCHESTER, Minnesota — Dasatinib, a drug that often is used to treat certain types of leukemia, may have antidiabetic effects comparable to medications used to treat diabetes, and with more research may become a novel therapy for diabetic patients, according to new research published in Mayo Clinic Proceedings. Dasati nib is a tyrosine kinase inhibitor used to treat tumors and malignant tissue, as well as chronic myelogenous leukemia. Researchers at Mayo Clinic and the University of… (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - November 9, 2021 Category: Research Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves Asciminib, Drug With Novel Action in CML FDA Approves Asciminib, Drug With Novel Action in CML
This first-in-class STAMP inhibitor is approved for use in patients with chronic myeloid leukemia who have developed resistance to tyrosine kinase inhibitors.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 2, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Scemblix (asciminib) for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+ CML)
Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine kinase inhibitor (TKI) treatments1
In the pivotal... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 29, 2021 Category: Drugs & Pharmacology Source Type: news
FDA approves  asciminib for Philadelphia chromosome-positive chronic myeloid leukemiaÂ
On October 29, 2021, the Food and Drug Administration granted accelerated approval to asciminib (Scemblix, Novartis AG) for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 29, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and deb...
Source: Roche Media News - July 21, 2021 Category: Pharmaceuticals Source Type: news
FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and deb...
Source: Roche Investor Update - July 21, 2021 Category: Pharmaceuticals Source Type: news
Scientists identify protein markers related to the most common form of leukemia
(Wiley) Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. New research published in the Journal of Leukocyte Biology reveals that certain protein markers may indicate which patients have stable forms of CLL and which have more aggressive types. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2021 Category: Cancer & Oncology Source Type: news
Zydus Cadila gets tentative nod from USFDA to market cancer drug
"Ibrutinib belongs to a class of drugs known as kinase inhibitors and is used to treat certain cancers, such as mantle cell lymphoma or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Waldenstrom's macroglobulinemia," Zydus Cadila said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 21, 2021 Category: Pharmaceuticals Source Type: news
Two studies by CU Cancer Center researchers explore link between inflammation and leukemia
(University of Colorado Anschutz Medical Campus) Two recent collaborative publications by CU Cancer Center members Eric Pietras, Ph.D. and James DeGregori, Ph.D., provide insights into how chronic inflammation can serve as a key factor in the development of leukemia and other blood cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 28, 2021 Category: International Medicine & Public Health Source Type: news
